Updated President's Message and Corporate Profile
Grifols and OrphanPacific start commercializing Lynspad™ [alpha-1 proteinase inhibitor] to treat alpha-1 antitrypsin deficiency
[IPM(Innovative Pharma Model) Introduction Video] CMIC Group Released "Creative Service to Support Drug Development Journey in Japan" Video
Announcement of Japan’s regulator approves Grifols’ Lynspad™ [alpha1-proteinase inhibitor] for the treatment of alpha-1 antitrypsin deficiency
OrphanPacific, Inc. Receives Manufacturing and Marketing Approval of
ORLADEYO Capsules 150mg for Suppression of HAE Attacks in Japan
